Charles Schwab Investment Management Inc. Sells 6,284 Shares of Kodiak Sciences Inc. $KOD

Charles Schwab Investment Management Inc. cut its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 2.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 263,370 shares of the company’s stock after selling 6,284 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.50% of Kodiak Sciences worth $739,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of KOD. US Bancorp DE lifted its position in shares of Kodiak Sciences by 131.7% during the 1st quarter. US Bancorp DE now owns 9,282 shares of the company’s stock worth $26,000 after buying an additional 5,276 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $28,000. Aries Wealth Management purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $70,000. XTX Topco Ltd purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $126,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in Kodiak Sciences by 183.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company’s stock valued at $147,000 after purchasing an additional 9,560 shares during the period. Institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD opened at $8.62 on Wednesday. The company has a market cap of $455.31 million, a P/E ratio of -2.27 and a beta of 2.45. The firm’s fifty day moving average is $6.96 and its two-hundred day moving average is $4.75. Kodiak Sciences Inc. has a 52-week low of $1.92 and a 52-week high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.02). As a group, analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.

Analysts Set New Price Targets

KOD has been the subject of several recent research reports. HC Wainwright boosted their price target on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a research note on Monday, August 18th. Barclays increased their price target on shares of Kodiak Sciences from $4.00 to $7.00 and gave the stock an “underweight” rating in a research note on Thursday, August 14th. Finally, JPMorgan Chase & Co. raised shares of Kodiak Sciences from an “underweight” rating to a “neutral” rating and set a $15.00 price target for the company in a research note on Thursday, August 14th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Kodiak Sciences currently has an average rating of “Hold” and an average price target of $11.75.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.